Compare Adaptive Biotechnologies Corp (ADPT) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ross Stores, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Ross Stores, Inc. trades at $216.25 (market cap $68.86B). The key difference: Ross Stores, Inc. is far larger — about 20.7× Adaptive Biotechnologies Corp's market cap, and Ross Stores, Inc. pays a 0.83% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ROST | |
|---|---|---|
Market Cap | $3.33B | $68.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $240.13 |
52-Week Low | $10.24 | $127.59 |
Enterprise Value | $3.19B | $69.45B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Ross Stores (ROST) trades at $214.67, up 0.58% today, with strong fundamentals including 9.74% net income margin and 38.98% ROE. Recent earnings beats and a consensus price target of $259.00 suggest upside potential. Technicals are bearish near-term, but positive news highlights robust sales growth and expansion. Cash flow trends show volatility, with 2025 net cash flow negative but projected to rebound in 2026.
Outlook is positive driven by earnings momentum and store expansion, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is bullish with 64% buy ratings, supporting a growth-oriented view for investors seeking retail exposure with solid profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
